Bio-Rad Laboratories (BIO) Receivables (2009 - 2026)

Bio-Rad Laboratories (BIO) has reported Receivables for 18 consecutive years, with $450.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Receivables fell 5.71% year-over-year to $450.7 million in Q2 2026; TTM through Jun 2026 was $450.7 million, a 5.71% decrease from a year earlier, with the FY2025 full-year figure at $472.5 million, up 1.48% from the prior year.
• Receivables was $450.7 million for Q2 2026 at Bio-Rad Laboratories, up from $439.5 million in the prior quarter.
• Over five years, Receivables peaked at $513.1 million in Q1 2023 and troughed at $438.4 million in Q1 2025.
• A 5-year average of $470.2 million and a median of $469.7 million in 2022 frame the typical range for Receivables.
• Across the five-year window, Receivables rose 18.91% in 2022 and retreated 10.42% in 2024, its largest moves.
• Over 5 years, Receivables stood at $506.2 million in 2022, then retreated by 1.06% to $500.9 million in 2023, then slipped by 7.05% to $465.6 million in 2024, then rose by 1.48% to $472.5 million in 2025, then decreased by 4.61% to $450.7 million in 2026.
• The last three Receivables figures came in at $450.7 million (Q2 2026), $439.5 million (Q1 2026), and $472.5 million (Q4 2025), per Business Quant data.